Weight of Evidence and Human Relevance Evaluation of the Benfluralin Mode of Action in Rats (Part II): Thyroid carcinogenesis.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 26 01 2020
revised: 10 07 2020
accepted: 13 07 2020
pubmed: 18 8 2020
medline: 9 7 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Benfluralin is an herbicide of the dinitroaniline class used to control grasses and weeds. In a 2 year dietary study in rats, benfluralin increased incidences of thyroid follicular adenoma and carcinoma at high dietary concentrations (≥2500 ppm). The benfluralin toxicology database suggests the mode of action (MOA) is initiated by induction of liver metabolizing enzymes, particularly thyroid hormone specific UGTs, a major pathway for T4 clearance in rats. As reported with phenobarbital, this effect triggers negative feedback regulation, increasing thyroid stimulating hormone (TSH) release into circulating blood. When sustained over time, this leads to thyroid changes such as follicular hypertrophy, hyperplasia and thyroid follicular tumors with chronic exposures. The described MOA was previously established in rat studies with various chemical activators of xenobiotic receptors in the liver. It is generally considered as non-relevant in humans, due to differences between humans and rats in T4 turnover and susceptibility to this carcinogenic MOA. A structured methodology based on the IPCS/MOA/Human Relevance framework was used in the evaluation of available benfluralin data, and the conclusion was determined that the carcinogenic potential of benfluralin in the thyroid is not relevant in humans.

Identifiants

pubmed: 32798613
pii: S0273-2300(20)30162-8
doi: 10.1016/j.yrtph.2020.104736
pii:
doi:

Substances chimiques

Thyroid Hormones 0
Toluidines 0
benefin 28224BUY6R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104736

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Christian Strupp (C)

Gowan, Highlands House, Basingstoke Road, Spencers Wood Reading, Berkshire, RG7 1NT, United Kingdom. Electronic address: CStrupp@gowanco.com.

Nicolas Quesnot (N)

Charles River Laboratories Evreux, 27005, Evreux Cedex, France. Electronic address: Nicolas.quesnot@crl.com.

Céline Weber-Parmentier (C)

KaLy-Cell, 67115, Plobsheim, France. Electronic address: c.parmentier@kaly-cell.com.

Lysiane Richert (L)

KaLy-Cell, 67115, Plobsheim, France. Electronic address: l.richert@kaly-cell.com.

Werner H Bomann (WH)

ToxConsult®, 9393 W 110th Street, 51 Corporate Woods, Suite 500, Overland Park, KS, 66210, USA. Electronic address: info@tox-consult.com.

Pramila Singh (P)

Charles River Laboratories Evreux, 27005, Evreux Cedex, France. Electronic address: Pramila.singh@crl.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH